Idsk -- BOSTON (EGMN) – Single-dose intravenous immunoglobulin may be an effective adjunctive therapy for patients with severe, recurrent Clostridium difficile colitis that is refractory to standard treatment, according to data presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy.
